
|Videos|August 9, 2022
Unmet Needs and Investigational Therapies in mCSPC
Author(s)Jason Hafron, MD
Dr Jason Hafron concludes his discussion of mCSPC by highlighting the need to work towards a cure for the disease, and two major clinical trials investigating triplet treatment regimens.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer
3
Individualizing androgen pathway therapy in mCSPC
4
BOND-003 Cohort C: Efficacy Results
5









